![uniQure N.V. logo](/logos/QURE.webp)
uniQure N.V.
NASDAQ:QURE
Overview | Financials
Company Name | uniQure N.V. |
Symbol | QURE |
Currency | USD |
Price | 5.42 |
Market Cap | 263,940,992 |
Dividend Yield | 0% |
52-week-range | 3.73 - 11.35 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Matthew Craig Kapusta |
Website | https://www.uniqure.com |
An error occurred while fetching data.
About uniQure N.V.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD